RESUMO
Toxoplasma gondii is an obligate intracellular parasite with global incidence. The acute infection, toxoplasmosis, is treatable but current regimens have poor host tolerance and no cure has been found for latent infections. This work builds upon a previous high throughput screen which identified benzoquinone acyl hydrazone (KG8) as the most promising compound; KG8 displayed potent in vitro activity against T. gondii but only marginal in vivo efficacy in a T. gondii animal model. To define the potential of this new lead compound, we now describe a baseline structure-activity relationship for this chemotype. Several derivatives displayed IC50's comparable to that of the control treatment pyrimethamine with little to no cytotoxicity. The best of these, KGW44 and KGW59, had higher metabolic stability than KG8. In an in vivo T. gondii murine model, KGW59 significantly increased survivorship. This work provides new insights for optimization of this novel chemotype.
Assuntos
Antiparasitários/farmacologia , Antiparasitários/uso terapêutico , Benzoquinonas/farmacologia , Benzoquinonas/uso terapêutico , Hidrazonas/farmacologia , Toxoplasma/efeitos dos fármacos , Animais , Antiparasitários/efeitos adversos , Antiparasitários/química , Benzoquinonas/efeitos adversos , Benzoquinonas/química , Linhagem Celular , Modelos Animais de Doenças , Descoberta de Drogas , Feminino , Humanos , Hidrazonas/química , Hidrazonas/uso terapêutico , Concentração Inibidora 50 , Camundongos , Pirimetamina/administração & dosagem , Pirimetamina/uso terapêutico , Relação Estrutura-Atividade , Toxoplasmose/tratamento farmacológico , Toxoplasmose/parasitologiaRESUMO
We profiled three novel T. gondii inhibitors identified from an antimalarial phenotypic high throughput screen (HTS) campaign: styryl 4-oxo-1,3-benzoxazin-4-one KG3, tetrahydrobenzo[b]pyran KG7, and benzoquinone hydrazone KG8. These compounds inhibit T. gondii in vitro with IC50 values ranging from 0.3 to 2µM, comparable to that of 0.25 to 1.5µM for the control drug pyrimethamine. KG3 had no measurable cytotoxicity against five mammalian cell lines, whereas KG7 and KG8 inhibited the growth of 2 of 5 cell lines with KG8 being the least selective for T. gondii. None of the compounds were mutagenic in an Ames assay. Experimental gLogD7.4 and calculated PSA values for the three compounds were well within the ranges predicted to be favorable for good ADME, even though each compound had relatively low aqueous solubility. All three compounds were metabolically unstable, especially KG3 and KG7. Multiple IP doses of 5mg/kg KG7 and KG8 increased survival in a T. gondii mouse model. Despite their liabilities, we suggest that these compounds are useful starting points for chemical prospecting, scaffold-hopping, and optimization.
